Key result
Spironolactone (50-100 mg/day) reduced vascular collagen turnover and improved time-domain heart rate variability compared to placebo in patients with stable chronic heart failure.
Why the study?
Does spironolactone reduce vascular collagen turnover and improve heart rate variability in patients with stable chronic heart failure?
Population
31 patients with stable chronic heart failure (CHF)
Comparison
Spironolactone in addition to diuretics and… vs Placebo in addition to diuretics and angiotensin…
Design
RCT, randomised, double-blind
Authors
Loading...
Supports spironolactone addition in stable HF for antifibrotic and HRV benefits; extends prior outcome data with mechanistic RCT evidence.
RCT (n=31)
Double-blind
Randomized
Does spironolactone reduce vascular collagen turnover and improve heart rate variability in patients with stable chronic heart failure?
Spironolactone added to standard therapy in stable CHF patients reduces vascular collagen turnover and improves heart rate variability, particularly during early morning hours.
R. MacFadyen (1997) conducted an RCT in Stable chronic heart failure (CHF) (n=31). Spironolactone vs. Placebo was evaluated on Circulating levels of procollagen type III N-terminal amino peptide and time-domain parameters of heart rate variability. Spironolactone (50-100 mg/day) reduced vascular collagen turnover and improved time-domain heart rate variability compared to placebo in patients with stable chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: